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ABSTRACT 
There are many genes that encode proteins for cell proliferation, differentiation, and development. Mutations in 
these genes can affect its function. Accumulation of genetic alteration through mutations or epigenetic event 
plays an important role in cancer progression. One such gene presumed to be linked to cancer is the Tumor 
Susceptibility Gene 101 (TSG101). However, many research studies failed to detect genomic alteration in this 
gene yet these studies have shown that the TSG101 undergoes alternative and aberrant splicing. Therefore, this 
study was proposed to detect whether the nucleotide variations and/or mutations of the TSG101 diverge in 
different human tissue types via restriction site characterization. Besides that, it is also to observe whether any of 
the nucleotide variations dominate certain cancer types. Briefly, total RNA from nasopharyngeal carcinoma, oral 
carcinoma and bladder carcinoma was transcribed into cDNA prior proceeding to polymerase chain reaction 
(PCR) using several sets specific of TSG101 primer. Subsequently, the PCR product was purified and subjected 
to restriction enzyme digestion. Agarose gel electrophoreses analysis of TSG101 partial sequence indicated that 
there is no mutation found at the specific restriction site in all tissues samples studied. Hence, mutational 
alteration might not be the main event in all the cancer studied. Nevertheless, sequencing of the TSG101 full 
length will provide more accurate and reliable results. Epigenetic studies of TSG101 can be considered to further 
elucidate the genetic alteration of this gene that leads to cancer.  
 





Terdapat banyak gen yang mengekod untuk protein bagi fungsi proliferasi, pembezaan dan perkembangan sel. 
Mutasi yang berlaku atas gen-gen ini boleh mempengaruhi fungsi mereka. Perubahan genetik yang terkumpul  
dari proses mutasi atau kejadian epigenetik memainkan peranan penting dalam perkembangan kanser. Salah satu 
gen yang dihubungkaitkan dengan kanser ialah Tumor Susceptibility Gene 101 (TSG101). Kebanyakan 
penyelidikan yang dijalankan gagal menemui sebarang perubahan genomik dalam gen ini  namun ada 
penyelidikan yang  menunjukkan bahawa TSG101 menjalani percantuman alternatif dan juga percantuman 
abnormal. Sehubungan itu, kajian ini telah diusulkan untuk mengesan sama ada TSG101 mempunyai variasi 
nukleotida dan/atau mutasi berbeza di dalam tisu manusia yang berlainan. Selain itu, kajian ini juga bertujuan 
melihat sama ada variasi-variasi ini mendominasi tisu kanser yang tertentu. Secara ringkasnya, RNA penuh dari 
carcinoma nasopharygeal, oral, bladder dan colon telah ditranskripkan ke cDNA yang kemudiannya digunakan 
dalam proses rantaian polymerase (PCR) dengan beberapa set primer TSG101 yang spesifik. Produk PCR 
kemudiannya ditulenkan dan dilalukan percernaan enzim restriksi. Proses elektroforesis gel agarose bagi jujukan 
partial TSG101 telah menunjukkan bahawa tiada sebarang mutasi berlaku di lokasi spesifik kepada enzim 
restriksi untuk semua jenis tisu manusia yang dikaji. Oleh yang demikian, boleh dikatakan yang perubahan jenis 
mutasi dalam TSG101 bukan kejadian utama dalam kanser-kanser yang dikaji. Namun demikian, proses 
penjujukan bagi koding TSG101 akan memberi keputusan yang lebih jitu dan sahih. Selain itu, kajian epigenetik 
TSG101 boleh dipertimbangkan untuk penjelasan perubahan genetik yang berlaku pada gen ini yang 
menyebabkan kanser.  
 






Cancer is the more virulent form of neoplasia, a disease process characterized by uncontrolled 
cellular proliferation leading to a mass or tumour and it has to be malignant in order to be 
termed cancer (Nussbaum et al., 2004).  
 
Cancer is presumed to occur through a multi-step process involving sequential cycles of 
mutation and selection (Calabrese et al., 2005). Different types of mutations are responsible 
for causing cancer which include mutations such as activating gain of function mutations of 
one allele of a proto oncogene, loss of function of both alleles or dominant negative mutations 
of one allele of tumour suppressor gene, and chromosomal translocation that will alter the 
expression of genes or create chimeric genes encoding proteins that have gained more than 
one functional property (Nussbaum et al., 2004). These genetic abnormalities affect a number 
of identified pathways that are involved in carcinogenesis (Lüchtenborg et al., 2005). 
 
There are many genes that encode proteins of cell proliferation, differentiation, and 
development. If these genes undergo mutations, their functions will be affected (Sherr, 2004). 
Once initiated, a cancer progresses by accumulating other genetic damage through more 
mutations or epigenetic silencing of the genes that encode the cellular machinery that repair 
damaged DNA and maintains cytogenetic normality (Nussbaum et al., 2004). 
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One such gene presumed to be linked to cancer is the Tumor Susceptibility Gene 101 
(TSG101). The TSG101 was initially thought to be a tumour suppressor gene. However, many 
research studies that were conducted failed to detect genomic alteration yet these studies have 
shown that this gene undergoes alternative and aberrant splicing. Some studies have shown 
the gene to be overexpressed in certain carcinomas.  
 
Therefore, this proposed study is to detect whether the nucleotide variations and/or mutations 
of the TSG101 diverge in different human tissue types. Besides that, it is also to observe 
whether any of the nucleotide variations dominate certain cancer types.  
 
 In this study, a restriction sites comparison of the TSG101 among different tumour tissues 
will be made using restriction enzyme analysis, which is suitable for direct detection of 
mutations (Cotton, 1997). In most studies done, the researchers have opted for DNA 
sequencing to screen for nucleotide variation. However, DNA sequencing is a costly method, 
therefore in this study a cheaper but highly reproducible method (Strachan and Read, 1999) 
which is restriction enzyme analysis will be used. According to Cotton (1997), a mutation can 
be detected by restriction analysis by the alteration in the range of fragments seen on gel 
electrophoresis.  
 
Restriction enzyme analyses are performed using Type II restriction endonucleases which are 
isolated from a wide diversity of bacterial genera (Hill, n.d.). Basically, restriction 
endonucleases are defined as double stranded DNases that recognize specific DNA sequences 
and make double stranded cleavage at defined point within or close to that sequence (Roberts 





The main objective of this study is to compare the specific bands produced from the 
restriction enzyme digestion of the amplified gene segment for all available normal and 




2.0 LITERATURE REVIEW 
 
2.1 Tumor Susceptibility Gene 101 (TSG101) 
 
The human Tumor Susceptibility Gene 101 (TSG101) has been mapped to chromosome 
11p15.1-p15.2 (Li et al., 1997 cited in Wagner et al., 1998). This site has shown loss of 
heterozygosity in many different types of tumours (Wagner et al., 1998). The TSG101 gene 
has 10 exons which is about 46.63 Kb (Genatlas, 2006). TSG101 encodes a 391 amino acids 
protein (Genatlas, 2006). This protein is usually localized in the cytoplasm (Zhong et al., 1997 
cited in Wagner et al., 1998). However, it can also be detected in the nucleus depending on 
the stage of the cell cycle and it can also co-localize with the mitotic spindle apparatus during 
cell division (Xie et al., 1998 cited in Wagner et al., 1998).  
 
2.2 Structure and Function of Tumor Susceptibility Gene 101 (TSG101) 
 
The TSG101 has a few highly conserved regions, which are: 
i. A C-terminal coiled coil domain which is said to interact with stathmin which is cell 
growth regulating protein. (Maucuer et al., 1995 cited in Wagner et al., 1998; Krempler et al., 
2002).  This region is also said to be involved in a potential co-repressor activity (Krempler et 
al., 2002). 
ii. A proline rich region known to exist in activation domains of transcriptional factors 
(Wagner et al., 1998). 
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iii. The N-terminal region which is similar to the catalytic domain of ubiquitin 
conjugating enzymes. This suggests the potential of TSG101 as a regulator in ubiquitin 
mediated protein degradation. (Koonin and Abagyan, 1997; Ponting et al., 1997 both cited in 
Wagner et al., 1998). The ubiquitin conjugating enzymes are dominant negative regulators of 
the cell cycle control (Krempler et al., 2002). Besides that, Krempler and his co-workers 
(2002) also stated that this domain is said to interact with the cell cycle regulator MDM2. 
 
According to Wagner et al. (1998), due to the highly conserved motifs, TSG101 is believed to 
have different functions at specific stages of the cell cycle. The authors also mentioned that 
due to TSG101 potential as a regulator of protein regulation, it could influence the half life of 
other tumour suppressor genes and regulatory protein of the cell cycle.  In one such case, Li et 
al. (2001) have pointed out that the TSG101 participates with MDM2 in a separate feedback
 
control loop that affects MDM2 stability and therefore affecting p53/MDM2
 
feedback 
regulation. Li and co-workers (2001) showed that TSG101 is an inhibitor
 
of ubiquitination. 
They had also found that TSG101 can bind to both p53 and
 
MDM2. The MDM2/p53 circuitry 
when deregulated will result in tumorigenesis (Liu et al., 2002). This ability of TSG101 to 
interact with MDM2 and/or p53 has functional consequences
 
on the steady-state levels of 
MDM2 and p53 (Li et al., 2001).  
 
Xie et al. (1998) observed that the inactivation of TSG101 was associated with abnormal 
microtubule organizing centres and nuclear anomalies; hence they suggested that the absence 
of the TSG101 protein or the lack of individual TSG101 domains may lead to chromosomal 
instability and consequently a progression of tumorigenesis (cited in Wagner et al., 1998). 
However, according to Li et al. (2001) overexpression of TSG101 mRNA
 
in either the sense 
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or antisense direction can lead to neoplastic
 
transformation, whereas the total absence of 
TSG101 could result in p53 accumulation, cell growth arrest, and early
 
embryonic death. This 
was due to the complicated effects of TSG101 on growth regulatory proteins and pathways 
particularly MDM2 and p53 (Li et al., 2001). 
 
2.3 Bladder Cancer 
 
The bladder is a hollow organ with flexible muscular walls located in the lower abdomen 
(Calvagna, 2007). It is used to store urine (Calvagna, 2007). According to second report of the 
National Cancer Registry in year 2003, the bladder cancer incidence per 100 000 populations 
in the Peninsular is 2.5 for both sexes (Lim and Halimah, 2004). It is also stated in the report 
that, the bladder cancer highly occurs in Malay males (52.6%) and both Malay and Chinese 
females (47.1%). 
 
The cancers of bladder are named after the cell type that forms the cancer (Calvagna, 2007). 
There are three main cell types hence three different cancers of the bladder. First, is the 
transitional cell carcinoma or also known as urothelial carcinoma which are from the 
transitional cells forming the innermost lining of the bladder wall (eMedicineHealth, 2005) 
which accounts for 90% of bladder cancers (Calvagna, 2007). Second is the squamous cell 
carcinoma which forms from the thin, flat cells because of some form of inflammation or 
irritation that has taken place for many months or years (eMedicineHealth, 2005). Finally, the 
third type is the adenocarcinoma which is formed from the cells that make up glands 
(eMedicineHealth, 2005).  Among the risk factors for bladder are presumed to be caused by 
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tobacco smoking, amount of liquid intake, occupational exposures and infection by 
Schistosoma haematobium (Tyczynski and Parkin, 2003).  
 
2.4  Colorectal cancer 
 
According to American Cancer Society (2005), colorectal cancer is the cancer which develops 
in colon or the rectum. The process of forming cancer usually begins with the non-cancerous 
polyps which eventually becomes cancer. Adenomatous polyps are more likely to become 
cancerous. Adenocarcinomas which evolve from the glandular tissue make up a total of 95% 
of colorectal cancers (American Cancer Society, 2005).  In Malaysia, the colorectal cancer 
account for 14.2% and 10.1% for male and female respectively. It is the commonest cancer in 
male and the third commonest in women according to the National Cancer Registry (Lim and 
Halimah, 2004). 
 
2.5 Nasopharyngeal Cancer (NPC) 
 
Nasopharyngeal cancer occurs in the nasopharynx area which is located in the back of the 
nose toward the base of skull (American Cancer Society, 2006). The frequency the different 
types occurring vary according geographical area (American Cancer Society, 2006). 
According to the National Cancer Registry report, the nasopharyngeal cancer is the second 
most common cancer among men in Malaysia which is 8.8% of the total male cancers (Lim 
and Halimah, 2004). The male to female ratio for this cancer is 2.75 to 1 (Lim and Halimah, 




Figure 1: Sagittal magnetic resonance image in a patient with newly diagnosed squamous cell 
carcinoma of the nasopharynx. The arrows denote the primary tumor and a lateral retropharyngeal 
node metastasis. Taken from: www.Aafp.org/afp. 
 
 
Basically, there are three types of NPC which are Type I, Type II and Type III NPC. Type I is 
the keratinizing squamous cell carcinoma, while Type II is the non-keratinizing carcinoma, 
whereas Type III is the undifferentiated carcinoma (American Cancer Society, 2006).  Among 
the risk factors said to cause NPC is the consumption of salted-fish and other salt preserved 
food, occupational hazards like dust and smoke particles. Besides that, NPC is also said to be 
linked to the Epstein Barr virus (Her, 2001).  
 
2.6 Oral Cancer 
 
Oral cancer occurs in the oral cavity which includes the lips, the inside lining of the lips and 
cheeks (buccal mucosa), the teeth, the gums, the front two-thirds of the tongue, the floor of 
the mouth below the tongue, the hard palate, and the area behind the retromolar trigone 
(American Cancer Society, 2006). According to Peterson (2003), oral cancer prevails in men 
and is the eighth most common cancer worldwide. According to author in the World Oral 
Health Report in 2003, this cancer ranks amongst the three most common types of cancer in 
South Central Asia.  
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Leukoplakia and erythroplakia are abnormal areas in the mouth or throat which are usually 
white and red respectively. These may be a cancer or a precancerous condition called 
dysplasia (American Cancer Society, 2006). However, most oral cancers are squamous cell 
carcinomas which begin in the squamous cells that line of the oral cavity and oropharynx 
(American Cancer Society, 2006). Another type of oral cancer is the verrucous carcinoma 
which also is a type of low grade squamous cell carcinoma that rarely metastasizes but can 
deeply spread into surrounding tissue (American Cancer Society, 2006). 
 
2.7 Tumor Susceptibility Gene 101 (TSG101) and Human Cancers 
 
The TSG101 have been linked with many types of tumours such as breast cancers (Wagner et 
al., 1998; Balz et al., 2002; Carney et al., 1998), ovarian cancers (Balz et al., 2002; Carney et 
al., 1998), papillary thyroid carcinomas (Liu et al., 2002), cervical carcinomas (Klaes et al., 
1999), prostate cancer (Sun et al., 1997) and liver cancers (Chen et al., 1999). However, in 
most studies done, genetic alteration such as somatic mutations and rearrangement are 
infrequent in TSG101. Most findings revealed the presence of aberrant splice forms of the 
TSG101. According to Wagner et al. (1998), most of the aberrant transcripts found were 
actually true alternative splice forms which were formed by exon skipping. Nevertheless, 
Wagner and co-workers (1998) did mention that the shorter transcripts reported (Lee and 
Feinberg, 1997) are probably real aberrant splice forms because it does not encode for any 
functional domain of the TSG101 protein. There have been suggestions that the shorter 
transcripts are caused by splicing events at either existing intron to exon junctions which 
produce alternative spliced products (Wagner et al., 1998) or cryptic splice donor and 
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acceptor sites within exons which causes aberrant splicing (Wagner et al., 1998; Lee and 
Feinberg, 1997). 
 
The TSG101 has been a controversial gene because not only were aberrant transcripts and 
alternative splice forms found in cancerous cells, they are also found in normal cells (Klaes et 
al., 1999; Carney et al., 1998; Chang et al., 1999; Lee and Feinberg, 1997; Xu et al., 1998). 
However, there have also been reports where no aberrant transcripts or any mutations of the 
TSG101 detected in the both the cancer cells and normal cells (Trink et al., 1998). There has 
also been a proposed argument saying that the aberrant transcripts could actually also be PCR 
artifacts. However, Balz and colleagues (2002) refuted this statement because from their 
work, the aberrant transcripts were detected in the breast cancer patient, patient’s mother who 
has breast cancer and not in the healthy daughter. 
 
Besides that, the TSG101 gene has also been known to be overexpressed in human cancers. In 
2002, Liu et al. demonstrated by using immnunohistochemistry and in situ hybridization that 
TSG101 was overexpressed in papillary thyroid carcinomas. In the study of differentially 
expressed genes using DNA microarray technology by Sim et al. (2006), the TSG101 gene 
was consistently up-regulated in colorectal cancer. The authors also mentioned that this gene 
is listed as an up-regulated gene of colorectal cancers in the Cancer Gene Expression 






3.0 MATERIALS AND METHODS 
 
3.1 Total RNA 
 
The total RNA for oral sample, bladder tumour samples and nasopharyngeal tumour and 
normal samples were obtaining from Chia Sze Wooi, Nur Diana Anuar and Joy Tan (personal 
communication; Immunology Laboratory, Dept of Molecular Biology, UNIMAS). 
 
Table 1: RNA Samples obtained from the immunology lab and their classification. 
Samples Type of sample 
(normal/tumour) 
















All samples are 
high grade 
transition cell 
















5. S18T Tumour 















2. HS59 Tumour Type II 
3. HS60 Tumour Type II 
4. HS65 Tumour Type III 
 
Colon Samples 
1. CN 
2. CT 
 
 
Normal 
Tumour 
 
 
Normal (Healthy) 
 
 
Chemicon 
Adenocarcinoma 
 
